The role of targeted therapy and biomarkers in breast cancer treatment

被引：0

作者：

Alison T. Stopeck

Ursa Brown-Glaberman

Hong Yuen Wong

Ben Ho Park

Sara E. Barnato

William J. Gradishar

Clifford A. Hudis

Hope S. Rugo

机构：

[1] University of Arizona Cancer Center,

[2] The Sidney Kimmel Comprehensive Cancer Center,undefined

[3] Johns Hopkins University,undefined

[4] Johns Hopkins,undefined

[5] Robert H. Lurie Comprehensive Cancer Center,undefined

[6] Northwestern University Feinberg School of Medicine,undefined

[7] Weill Cornell Medical College,undefined

[8] Memorial Sloan-Kettering Cancer Center,undefined

[9] Helen Diller Family Comprehensive Cancer Center,undefined

[10] University of California,undefined

[11] San Francisco,undefined

来源：

Clinical & Experimental Metastasis | 2012年 / 29卷

关键词：

Breast cancer; Targeted therapy; Biomarkers; Chemotherapy; Angiogenesis; Her2;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Breast cancer is the most prevalent life-threatening cancer in women and the second leading cause of cancer associated deaths. Consequently, optimizing breast cancer therapy to increase cure rates in early stage disease and improve life expectancy and palliation for patients with metastasis is a critical need and major area of research in medical oncology. This article focuses on the development of personalized therapy in breast cancer though the use of targeted therapies and their associated biomarkers. Topics reviewed include the historic advances in targeting the HER2 receptor and the current avenues being studied to circumvent resistance; new developments in the management of triple negative and metastatic breast cancer; and the challenges and pitfalls associated with targeting angiogenesis. Using these as examples, many of the innovations and challenges in the treatment of women with breast cancer are explored.

引用

页码：807 / 819

页数：12

共 181 条

[1]

Slamon DJ(2001)Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783-792

[2]

Marty MA(2005)Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 4265-4274

[3]

Cobleigh MA(2005)Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 2639-2648

[4]

Robert N(2006)Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER2-overexpressing metastatic breast cancer J Clin Oncol 24 2786-2792

[5]

Wardley AM(2010)Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer J Clin Oncol 28 976-983

[6]

Chan A(2006)Vinorelbine plus trastuzumab combination as first-line therapy for HER2-positive metastatic breast cancer patients: an international phase II trial Br J Cancer 95 788-793

[7]

Yardley DA(2009)Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer Clin Breast Cancer 9 178-183

[8]

Ewer MS(2005)Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment J Clin Oncol 23 7820-7826

[9]

de Azambuja E(2009)Cardiac toxicity with anti-HER2 therapies: what have we learned so far? Target Oncol 4 77-88

[10]

Geyer CE(2006)Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733-2743

← 1 2 3 4 5 6 7 8 9 10 →